GSK: to present data on multiple myeloma treatment

(CercleFinance.com) - GlaxoSmithKline said that it will present new data from a clinical trial on its investigational antibody-drug belantamab mafodotin in relapsed/refractory multiple myeloma at the upcoming European Hematology Association (EHA) congress.


In all, sixteen presentations will be shared at the meeting, including new analyses from a pivotal study assessing belantamab mafodotin in heavily pre-treated patients with relapsed/refractory multiple myeloma, GSK said.

Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable.

The upcoming virtual edition of the European Hematology Association (EHA) annual congress will take place from 11 to 21 June.

Copyright (c) 2020 CercleFinance.com. All rights reserved.